|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Marketable securities | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Due from related parties | ||||||||||||||||||||
| Related-Party | ||||||||||||||||||||
| Total due from related parties | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Related-Party | ||||||||||||||||||||
| Non-related Party | ||||||||||||||||||||
| Total prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Marketable securities, noncurrent | ||||||||||||||||||||
| Property, plant and equipment, net | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Goodwill and intangible assets, net | ||||||||||||||||||||
| Long-term inventories, net | ||||||||||||||||||||
| Convertible note receivable | ||||||||||||||||||||
| Operating lease right-of-use assets, net | ||||||||||||||||||||
| Related-Party | ||||||||||||||||||||
| Non-related Party | ||||||||||||||||||||
| Total operating lease right-of-use assets, net | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Related-Party | ||||||||||||||||||||
| Non-related Party | ||||||||||||||||||||
| Total other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Related-Party | ||||||||||||||||||||
| Non-related Party | ||||||||||||||||||||
| Accrued expenses and other liabilities | ||||||||||||||||||||
| Related-party promissory notes, net of discounts and deferred issuance costs (Note 10) | ||||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||||
| Related-Party | ||||||||||||||||||||
| Non-related Party | ||||||||||||||||||||
| Total operating lease liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Related-party nonconvertible note, net of discount (Note 12) | ||||||||||||||||||||
| Related-party convertible note payable, at fair value | ||||||||||||||||||||
| Related-Party | ||||||||||||||||||||
| Total related-party convertible note payable, at fair value | ||||||||||||||||||||
| Related-party convertible note payable, at fair value (Note 7 and Note 12) | ||||||||||||||||||||
| Revenue interest liability | ||||||||||||||||||||
| Operating lease liabilities, less current portion | ||||||||||||||||||||
| Related-Party | ||||||||||||||||||||
| Non-related Party | ||||||||||||||||||||
| Total operating lease liabilities, less current portion | ||||||||||||||||||||
| Derivative liabilities | ||||||||||||||||||||
| Warrant liabilities | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders’ deficit: | ||||||||||||||||||||
| Common Stock, $0.0001 par value; 1,650,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 1,053,221,645 and 1,011,800,008 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively; excluding treasury stock, 163,800 shares outstanding as of June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||||||||
| Total ImmunityBio stockholders’ deficit | ||||||||||||||||||||
| Noncontrolling interests | ||||||||||||||||||||
| Total stockholders’ deficit | ||||||||||||||||||||
| Total liabilities and stockholders’ deficit | ||||||||||||||||||||
| Common stock, par value (in dollars per share) | ||||||||||||||||||||
Loading...
